ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2025
Pharmacist-Led Deprescribing of Aspirin for Primary Prevention of Cardiovascular Disease Among Geriatric Veterans.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aspirin is a commonly prescribed antiplatelet agent for primary and secondary prevention of cardiovascular events. Guidelines recommend avoiding aspirin for primary prevention in most patients aged ≥ 70 years, but there is limited data on the most effective way to deprescribe aspirin in outpatient settings. Methods: This prospective quality improvement study used the US Department of Veterans Affairs (VA) VIONE medication safety dashboard to identify eligible patients at a Durham VA Health Care System (DVAHCS) community-based outpatient clinic. Patients were aged ≥ 70 years without known atherosclerotic cardiovascular disease and an active aspirin prescription as of September 1, 2022. Two pharmacists gave a deprescribing presentation to primary care practitioners (PCPs) 90 days later. The primary objective was to compare the efficiency of pharmacist direct deprescribing of aspirin with PCP deprescribing for primary prevention over a 12-week period following the education session. Secondary objectives assessed the number of aspirin orders discontinued, the effect of the education on aspirin deprescribing for primary prevention, and pharmacist time to complete the intervention. Results: Two aspirin orders were deprescribed per hour of pharmacist time compared with 67 aspirin orders per hour for PCPs. In the 12 weeks following the PCP education session, 230 aspirin orders were discontinued, 97 by pharmacists and 133 by PCPs. Among the 868 patients identified, 224 met inclusion criteria for the pharmacist direct deprescribing intervention, and all patients were eligible through the PCP education method. Pharmacists spent about 48 hours on the pharmacist intervention and 1 hour on the PCP education intervention. Conclusions: PCP education was more efficient for deprescribing aspirin compared with direct deprescribing by pharmacists based on the number of aspirin orders discontinued by time spent.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.